Would you recommend PMRT in a male patient with a T2N0 breast cancer?

In the absence of strong data for men, typically the adjuvant recommendations are extrapolated from the women's literature and node positive patients appear to benefit from PMRT. This SEER analysis is the most robust dataset published, thus far. N0 patients do not appear to benefit, so unless this patient had other features (positive/close margin, triple negative, high grade/LVSI) that would make you consider PMRT in a woman with N0 disease, it's unclear that the patient would benefit from treatment.